Seeking to secure its own independence as M&A activity — whether real or rumoured — continues to convulse the pharma sector, Britain’s Shire is believed to be considering a bid for New Jersey-based NPS Pharmaceuticals, a rare disease specialist. According to usually well informed sources, Shire has been working quietly with advisers and held internal discussions about a potential cash offer for NPS, valuing the US business at just over $4bn. That would imply a bid pitched at around $40 a share,compared with NPS’s $27.50 market quote on Nasdaq on Friday.
Help employers find you! Check out all the jobs and post your resume.
